About Vasodilator-stimulated phosphoprotein
Vasodilator-stimulated phosphoprotein (VASP) is a protein
from Homo sapiens identified by UniProt accession
P50552, 380 residues long.
MolForge cross-references it against 0 known binders and
187 disease associations.
Target properties
| Protein name | Vasodilator-stimulated phosphoprotein |
|---|
| UniProt accession | P50552 |
|---|
| Gene | VASP |
|---|
| Organism | Homo sapiens |
|---|
| Length | 380 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (187)
Diseases linked to this target (Open Targets).
- breast adenocarcinoma · score 0.25
- glioblastoma multiforme · score 0.23
- neurodegenerative disease · score 0.21
- endometrial cancer · score 0.18
- head and neck squamous cell carcinoma · score 0.10
- hepatocellular carcinoma · score 0.10
- cancer · score 0.08
- drug use measurement · score 0.08
- thrombocytopenia 7 · score 0.08
- autosomal dominant macrothrombocytopenia · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P50552-F1 | alphafold | PREDICTED | 69.75 | — |
Amino-acid sequence (380 residues)
MSETVICSSR ATVMLYDDGN KRWLPAGTGP QAFSRVQIYH NPTANSFRVV GRKMQPDQQV VINCAIVRGV KYNQATPNFH QWRDARQVWG LNFGSKEDAA QFAAGMASAL EALEGGGPPP PPALPTWSVP NGPSPEEVEQ QKRQQPGPSE HIERRVSNAG GPPAPPAGGP PPPPGPPPPP GPPPPPGLPP SGVPAAAHGA GGGPPPAPPL PAAQGPGGGG AGAPGLAAAI AGAKLRKVSK QEEASGGPTA PKAESGRSGG GGLMEEMNAM LARRRKATQV GEKTPKDESA NQEEPEARVP AQSESVRRPW EKNSTTLPRM KSSSSVTTSE TQPCTPSSSD YSDLQRVKQE LLEEVKKELQ KVKEEIIEAF VQELRKRGSP
Explore Vasodilator-stimulated phosphoprotein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets